SEC Form 4 · accession 0001450324-16-000013
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas K. Equels
Officer — CEO,President · Director
Period of report
Jun 29, 2016
Accepted (ET)
Jul 1, 2016 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000946644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2016 | P | 30,000 | $0.1199 | A | 1,514,548 | D | |
| Common Stock | Jun 29, 2016 | P | 29,000 | $0.1197 | A | 1,543,548 | D | |
| Common Stock | Jun 30, 2016 | P | 28,000 | $0.12 | A | 1,571,548 | D | |
| Common Stock | Jun 30, 2016 | P | 28,000 | $0.119 | A | 1,599,548 | D | |
| Common Stock | Jul 1, 2016 | P | 28,000 | $0.1194 | A | 1,627,548 | D | |
| Common Stock | Jul 1, 2016 | P | 28,000 | $0.1186 | A | 1,655,548 | D |
Table II — derivative securities
No Table II lines on this filing.